February 6
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we are
Developing a new class of therapeutics that enhance the function of beneficial proteins
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectThe John Curtin School of Medical Research (JCSMR) is a multi-disciplinary institute. We excel in ground-breaking medical research in Cancer Biology; Immunology and Infectious diseases; Genomics; and Neuroscience.
ViewPeter Mac is one of the world’s leading cancer research, education and treatment centres globally and is Australia’s only public hospital solely dedicated to caring for people affected by cancer. There are over 2,500 staff, including more than 600 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.
ViewMelbourne Health’s research vision is to be a leading centre for to delivery of translational health, research and education.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreGround-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Read moreComing in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
Read moreENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
Read more